Tropinone reductase II
Tropinone reductase II (TRII) is an enzyme that plays a crucial role in the biosynthesis of tropane alkaloids, which are a class of alkaloids found in a variety of plant species. These alkaloids have significant pharmacological properties, including anticholinergic, stimulant, and anesthetic effects. TRII specifically catalyzes the reduction of tropinone to pseudotropine, a key step in the metabolic pathway leading to the production of various tropane alkaloids.
Function[edit | edit source]
TRII is involved in the biosynthetic pathway of tropane alkaloids, which are primarily synthesized in the roots of plants such as those belonging to the Solanaceae family, including Atropa belladonna (deadly nightshade), Coca (from which cocaine is derived), and Datura stramonium (jimsonweed). The enzyme catalyzes the stereospecific reduction of tropinone to pseudotropine, differing from Tropinone reductase I (TRI) which reduces tropinone to tropine. This reaction is critical as it dictates the type of alkaloids that will be produced downstream in the pathway.
Structure[edit | edit source]
The structure of TRII has been elucidated through various biochemical and crystallographic studies. It is a monomeric enzyme that requires NADPH as a cofactor for its reductive activity. The active site of TRII is specifically tailored to recognize and bind tropinone, facilitating its reduction to pseudotropine. The enzyme's structure is crucial for its specificity and catalytic efficiency.
Biological Significance[edit | edit source]
The production of tropane alkaloids is of considerable interest due to their wide range of pharmacological applications. Alkaloids such as scopolamine, hyoscyamine, and cocaine are used in medicine for their anticholinergic, analgesic, and anesthetic properties. The role of TRII in the biosynthesis of these compounds makes it a potential target for genetic and biochemical manipulation aimed at enhancing the production of specific alkaloids for pharmaceutical use.
Genetic Engineering[edit | edit source]
Advances in genetic engineering have allowed for the manipulation of the genes encoding TRII in various plant species. By overexpressing or silencing the TRII gene, researchers can influence the production of specific tropane alkaloids. This has implications for the pharmaceutical industry, where there is a demand for the large-scale production of these compounds.
Clinical Implications[edit | edit source]
Understanding the function and structure of TRII can also have clinical implications. For example, inhibitors of TRII could potentially be used to decrease the production of harmful alkaloids in plants, reducing the risk of poisoning from plants containing toxic tropane alkaloids. Conversely, enhancing TRII activity could increase the production of beneficial alkaloids used in medicine.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD